PHMMF (Pharma Mar) Scaled Net Operating Assets: 0.32 (As of Mar. 2026)


PHMMF Pharma Mar SA PHMMF
82 GF Score
Price $79.49
GF Value $91.39
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Scaled Net Operating Assets?

Pharma Mar PHMMF -25.35% 82 Scaled Net Operating Assets is 0.32 as of Mar. 2026. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $91.39 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Pharma Mar's operating assets for the quarter that ended in Mar. 2026 was $251.3 Mil. Pharma Mar's operating liabilities for the quarter that ended in Mar. 2026 was $101.8 Mil. Pharma Mar's Total Assets for the quarter that ended in Dec. 2025 was $462.6 Mil. Therefore, Pharma Mar's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.32.


Pharma Mar Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Scaled Net Operating Assets Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.21 0.20 0.30 0.43

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.40 0.30 0.39 0.32

PHMMF vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Pharma Mar's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Scaled Net Operating Assets falls into.


PHMMF
82GF Score
Pharma Mar SA PHMMF
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Pharma Mar's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(266.813-109.875)/366.119
=0.43

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=462.624 - 195.811
=266.813

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=167.738 - 42.954 - 14.909
=109.875

Pharma Mar's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(251.338-101.795)/462.624
=0.32

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=445.388 - 194.05
=251.338

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=156.751 - 39.857 - 15.099
=101.795

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.32 mean?
Pharma Mar (PHMMF) has a Scaled Net Operating Assets of 0.32 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Scaled Net Operating Assets too high?
Pharma Mar's current Scaled Net Operating Assets is 0.32. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Scaled Net Operating Assets compare to VRTX and REGN?
Pharma Mar's Scaled Net Operating Assets of 0.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Pharma Mar and its competitors. Pharma Mar's current Scaled Net Operating Assets is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.39, compared to a current price of $79.49 — trading 13% below its estimated fair value. The current Scaled Net Operating Assets is 0.32. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Scaled Net Operating Assets is 0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (PHMMF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of $79.49 is trading 13% below its estimated GF Value™ of $91.39. GuruFocus considers Pharma Mar to be Modestly Undervalued.

Key valuation signals for PHMMF:

  • Scaled Net Operating Assets: 0.32
  • GF Value™: $91.39 vs. price of $79.49 (13% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score

Get the complete analysis for PHMMF

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.49
Price
$91.39
GF Value